MORGAN STANLEY PLC/PUT/STRYKER CORP./300/0.1/20.12.24 Stock

Warrant

DE000ME0K5B6

Real-time Bid/Ask 04:06:00 2024-06-26 EDT
0.62 EUR / 0.66 EUR 0.00% Intraday chart for MORGAN STANLEY PLC/PUT/STRYKER CORP./300/0.1/20.12.24
Current month-5.88%
1 month-5.88%
Date Price Change
24-06-25 0.64 +10.34%
24-06-24 0.58 -10.77%
24-06-21 0.65 +3.17%
24-06-20 0.63 +28.57%
24-06-19 0.49 -7.55%

Delayed Quote Börse Stuttgart

Last update June 25, 2024 at 02:16 pm

More quotes

Static data

Product typeWarrant Plain-Vanilla
Buy / SellPUT
Underlying STRYKER CORPORATION
Issuer Morgan Stanley
WKN ME0K5B
ISINDE000ME0K5B6
Date issued 2023-09-12
Strike 300 $
Maturity 2024-12-20 (178 Days)
Parity 10 : 1
Emission price 3.18
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 4.96
Lowest since issue 0.48
Spread 0.05
Spread %7.58%

Company Profile

Stryker Corporation is one of the world's leaders in designing, manufacturing, and selling orthopedic equipments. Net sales break down by family of products as follows: - surgical equipments and neurotechnology products (57.5%): electric motorized surgical instruments, surgical navigation systems, endoscopy equipment, digital imaging systems, neurosurgery equipments, neurovascular devices, etc. The group also offers hospital beds, gurneys, stretchers, and emergency room equipment; - orthopedic implants (42.5%): joint prostheses, traumatology implants, micro-implants, orthopedic cement, orthobiology products, etc. The group also provides spinal implants. At the end of 2022, the group had 48 production sites worldwide. Net sales are distributed geographically as follows: the United States (73.9%), Europe/Middle East/Africa (12.7%), Asia/Pacific (10.2%) and other (3.2%).
Sector
-
More about the company

Ratings for Stryker Corporation

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Consensus: Stryker Corporation

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
339.6 USD
Average target price
372.9 USD
Spread / Average Target
+9.83%
Consensus